Centre for Biocatalytic Manufacture of New Modalities (CBNM)

在不断发展的药物和疾病治疗领域，新的、更具挑战性的药物靶标正在被确定，这些药物靶标需要更复杂的药物分子。这些复杂分子或“新模式”弥合了现有的两类化合物--小分子(如阿司匹林)和生物制品(抗体)之间的差距，通常比现有的小分子大，但比传统的生物制品小。这些新的分子类别作为新的治疗方法提供了巨大的前景，事实上，这些药物中的许多都是针对传统的小分子或抗体衍生药物无法解决的生物靶点。新模式的复杂性目前导致了较高的制造成本，这为开发生产这些化合物的较低成本路线提供了机会。小分子制造商受益于在制造战略中采用生物催化，并证明了这些催化剂在更广泛的化工生产中使用的潜力，如减少废流、降低能源成本和降低包括溶剂在内的商品成本。事实上，项目合作伙伴已经产生了一些早期的概念验证研究，并得到了更广泛的文献证据的支持，表明生物催化可以用于合成这些新模式。通过曼彻斯特大学、阿斯利康和Prozomix的合作，我们聚集了一系列不同的专家，这些专家将促进新制造战略的发展，以高效和清洁的方式生产这些新模式。生物催化的使用有可能使制药制造界无法获得的化学物质和对生产的控制。最终导致成本更低的制造，转化为更广泛的社区更多地获得下一代药物。

In the ever developing world of pharmaceuticals and treatments of diseases new, more challenging drug targets are being identified that require ever more complex drug molecules. These complex molecules or "New Modalities" bridge the gap between the two existing classes of compounds, small molecules (e.g. Aspirin) and biologics (Antibodies), and are typically larger than the existing small molecules but smaller than traditional biologics. These new classes of molecule offer great promise as novel therapies and indeed many of these medicines are aimed at biological targets that cannot be addressed by traditional either small molecule or antibody derived drugs. The complexity of the new modalities currently results in high cost of manufacture which offers an opportunity to develop lower cost routes to produce these compounds. Small molecule manufacturer has benefited from adopting biocatalysis within manufacturing strategies and has demonstrated the potential for use of these catalysts in wider chemical manufacture, such as reduced waste streams, lower energy costs and reduced costs of goods including solvents. Indeed, the project partners have already generated some early proof-of-concept studies, backed up by a wider literature evidence base suggesting that biocatalysis can be used in the synthesis of these new modalities.Through the partnership of the University of Manchester, AstraZeneca and Prozomix we are bringing together a diverse range of experts that will facilitate the development of new manufacturing strategies to produce these new modalities in an efficient and cleaner manner. The use of biocatalysis has the potential to allow access to chemistries and control of manufacture that are otherwise unavailable to the pharmaceutical manufacturing community. Culminating in lower cost manufacturing that translates into greater access to the next generation of drug for a wider community.